Silverarc Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Silverarc Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-26,374	Closed	-$3.84M	–	99
2022 Q2	$3.84M	Sell	26,374 -76,123	-74%	-$9.72M	1.18%	29
2022 Q1	$4.36M	Buy	102,497 +22,149	+28%	+$2.76M	1.8%	14
2021 Q4	$11.1M	Buy	80,348 +18,451	+30%	+$2.35M	4.49%	3
2021 Q3	$8.6M	Buy	61,897 +5,271	+9%	+$658K	4.86%	1
2021 Q2	$5.5M	Buy	56,626 +6,537	+13%	+$531K	2.45%	9
2021 Q1	$3.42M	Buy	50,089 +33,589	+204%	+$2.72M	1.87%	20
2020 Q4	$1.41M	Buy	+16,500	New	+$1.4M	0.82%	42

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SFM

Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Silverarc Capital Management's BHVN Position: Q3 2022 in Review

Silverarc Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 26,374 shares — an estimated $3.84M sold.

Silverarc Capital Management first reported a position in BHVN in Q4 2020 and held it in 7 quarters. The position peaked at $11.1M in Q4 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Silverarc Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Silverarc Capital Management sold 26,374 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $3.84M.
Silverarc Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 7 quarters.
Silverarc Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $11.1M in Q4 2021.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Silverarc Capital Management's 13F filing for Q3 2022, filed 28 Oct 2022.